Nectar Lifesciences Limited — Important, 10-03-2025: Granting/withdrawal/surrender/cancellation/suspension of key licenses/ regulatory approvals

Nectar Lifesciences Ltd. reports that its API manufacturing facility in Punjab underwent a joint inspection by the European Directorate for the Quality of Medicines & HealthCare (EDQM) and the Spanish Agency of Medicines and Medical Devices (AEMPS), resulting in seven observations, including four classified as critical. The company is currently preparing a Corrective Action and Preventive Action (CAPA) report to address these findings. A follow-up re-inspection by the European regulator could lead to EuGMP approval, emphasizing Nectar's commitment to maintaining high compliance and quality standards. This update could alter investor sentiment, presenting a cautious outlook as the company navigates the re-inspection process.